Axovant Sciences Ltd. (NYSE:AXON) will release its earnings data before the market opens on Monday, August 14th. Analysts expect Axovant Sciences to post earnings of ($0.53) per share for the quarter.

Axovant Sciences (NYSE:AXON) last announced its quarterly earnings results on Tuesday, June 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by $0.02. On average, analysts expect Axovant Sciences to post $-2.14 EPS for the current fiscal year and $-2.62 EPS for the next fiscal year.

Axovant Sciences Ltd. (AXON) opened at 23.40 on Monday. Axovant Sciences Ltd. has a 52 week low of $11.01 and a 52 week high of $26.49. The firm has a 50-day moving average of $22.85 and a 200 day moving average of $18.65. The stock’s market capitalization is $2.51 billion.

TRADEMARK VIOLATION NOTICE: “Axovant Sciences Ltd. (AXON) to Release Earnings on Monday” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/07/axovant-sciences-ltd-axon-to-release-earnings-on-monday.html.

AXON has been the topic of a number of recent analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $31.00 target price on shares of Axovant Sciences in a research report on Friday, June 9th. CIBC upped their target price on Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, June 14th. Oppenheimer Holdings, Inc. upped their target price on Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, June 14th. BidaskClub raised Axovant Sciences from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Finally, Zacks Investment Research lowered Axovant Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. Axovant Sciences currently has an average rating of “Buy” and a consensus target price of $28.50.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Earnings History for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.